# PolyPid Schedules Investor Day Ahead of Key FDA Decision for D-PLEX100

- URL: https://stocks.freetheai.org/news/polypid-schedules-investor-day-ahead-of-key-fda-decision-for-d-plex100-cb94b4
- Published: 2026-10-15T12:30:00Z
- Category: company_news; sentiment: neutral; impact: medium
- Symbols: [NASDAQ:PYPD](https://stocks.freetheai.org/symbols/NASDAQ-PYPD)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

PolyPid Ltd. (PYPD) will host a virtual Investor Day on Oct. 28, 2026. During the event, the company plans to present its 2030 corporate strategy, discuss its product pipeline, and introduce PD01B, a target treatment for diabetic foot infections. PolyPid shares traded down 1.02% at $4.83 following the update.

The announcement comes as the company approaches a key regulatory threshold for its lead product candidate, D-PLEX100. The U.S. Food and Drug Administration is conducting an accelerated review with a decision date set for Nov. 28, 2026. Investors will be watching the upcoming presentation for strategic updates and details regarding potential commercial execution ahead of the FDA ruling.

## Key points

- PolyPid Ltd. scheduled a virtual Investor Day for Oct. 28, 2026, to outline its 2030 strategy.
- Lead drug candidate D-PLEX100 is under FDA Priority Review with a decision target date of Nov. 28, 2026.
- The company is introducing PD01B, a pipeline expansion program for diabetic foot infections.
- PolyPid (PYPD) shares fell 1.02% to $4.83 in current trading.

## Questions and answers

### When is the PolyPid Investor Day?

PolyPid will host its virtual Investor Day on Oct. 28, 2026.

### What is the FDA review deadline for D-PLEX100?

The FDA set a target action date of Nov. 28, 2026, under Priority Review.

### What is the new program PolyPid is introducing?

PolyPid is introducing PD01B to address diabetic foot infections.